Evidence map›Paper›PMID 38431620›Full record

ArticleCancer cell international2024

A cuproptosis-related gene expression signature predicting clinical prognosis and immune responses in intrahepatic cholangiocarcinoma detected by single-cell RNA sequence analysis.

Hefei Ren, Chang Liu, Cheng Zhang, Hongkun Wu, Jiafeng Zhang, Zhenhua Wang, Lei Chen, Huiquan Wang, Chenghao Shao, Lin Zhou

Open access · goldAbstract read
In one paragraph

Article in Cancer cell international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Role of Ferredoxin 1Cancer pathogenesis and therapy · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Targeting cuproptosis in liver cancer: Molecular mechanisms and therapeutic implications.Apoptosis : an international journal on programmed cell death · 2025
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Hefei Ren *Department of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.
Chang Liu *Department of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.
Cheng Zhang *Institute of Aging & Tissue Regeneration, State Key Laboratory of Systems Medicine for Cancer and Stress and Cancer Research Unit of Chinese Academy of Medical Sciences (No. 2019RU043), Ren-Ji Hospital, Shanghai Jiao Tong University School of Medicine (SJTU-SM), Shanghai, 200127, China.
Hongkun WuDepartment of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.
Jiafeng ZhangDepartment of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.
Zhenhua WangDepartment of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.
Lei ChenDepartment of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.
Huiquan WangDepartment of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.
Chenghao ShaoDepartment of Pancreatic-Biliary Surgery, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, 200003, China. shaochenghao_czyy@163.com.
Lin ZhouDepartment of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, 200003, China. lynnzhou36@126.com.
Shanghai Changzheng Hospital · CNShanghai Jiao Tong University · CN

Funding

Leading Talent Project of Shanghai Huangpu District 2020-1-28National Natural Science Foundation of China 82072371National Natural Science Foundation of China 82102482National Natural Science Foundation of China 82372313Program of Shanghai Academic/Technology Research Leader 23XD1404900Shanghai Healthcare Commission Young Talent Program 2022YQ056Shanghai Science and Technology Committee under Grant 21ZR1478200
6 · The paper itself

Abstract

backgroundCholangiocarcinoma represents a malignant neoplasm originating from the hepatobiliary tree, with a subset of tumors developing inside the liver. Intrahepatic cholangiocarcinomas (ICC) commonly exhibit an asymptomatic presentation, rendering both diagnosis and treatment challenging. Cuproptosis, an emerging regulated cell death pathway induced by copper ions, has garnered attention recently. As cancer cells show altered copper metabolism and comparatively higher copper needs, cuproptosis may play a role in the development of ICC. However, studies investigating this possibility are currently lacking.

methodsSingle-cell and bulk RNA sequence data were analyzed, and correlations were established between the expression of cuproptosis-related molecules and ICC patient survival. Genes with predicting survival were used to create a CUPT score using Cox and LASSO regression and tumor mutation burden (TMB) analysis. The CIBERSORT software was employed to characterize immune cell infiltration within the tumors. Furthermore, immune infiltration prediction, biological function enrichment, and drug sensitivity analyses were conducted to explore the potential implications of the cuproptosis-related signature. The effects of silencing solute carrier family 39 member 4 gene (SLC39A4) expression using siRNA were investigated using assays measuring cell proliferation, colony formation, and cell migration. Key genes of cuproptosis were detected by western blotting.

resultsThe developed CUPT score divided patients into high and low CUPT score groups. Those with a low score had significantly better prognosis and longer survival. In contrast, high CUPT scores were associated with worse clinical outcomes and significantly higher TMB. Comparisons of the two groups also indicated differences in the immune infiltrate present in the tumors. Finally, we were able to identify 95 drugs potentially affecting the cuproptosis pathway. Some of these might be effective in the treatment of ICC. The in vitro experiments revealed that suppressing the expression of SLC39A4 in ICC cell lines resulted in reduced cell proliferation, colony formation, and cell migration. It also led to an increase in cell death and the upregulation of key genes associated with cuproptosis, namely ferredoxin 1 (FDX1) and dihydrolipoyl transacetylase (DLAT). These findings strongly suggest that this cuproptosis-associated molecule may play a pivotal role in the development and metastasis of ICC.

conclusionsChanges in the expression of a cuproptosis-related gene signature can predict the clinical prognosis of ICC with considerable accuracy. This supports the notion that cuproptosis influences the diversity and complexity of the immune microenvironment, mutational landscape, and biological behavior of ICC. Understanding this pathway better may hold promise for the development of innovative strategies in the management of this disease.

Indexed as

CuproptosisImmune microenvironmentIntrahepatic cholangiocarcinomaPrognostic signatureSingle-cell analysis

Identifiers

PMID38431620
PMCPMC10908169
OpenAlexW4392348359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.